In the fifth episode of a six-part interview series on immunotherapy, Marc Voigt, CEO and Executive Director of Immutep (ASX:IMM), explains the complex and heavily regulated process of bringing a new ...

Both studies, which are reporting the results of early-stage clinical trials, show that the interventions were safe, and that ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Revolutionary 'off-the-shelf' cancer vaccine designed to prevent the recurrence of oesophageal cancer ITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025 ...

has granted Clinical Trial Application (CTA) approval for the first-in-human Phase I/IIa clinical trial of ITOP1, the company's lead 'off-the-shelf' cancer vaccine. ITOP1 is a precision cancer ...

has granted Clinical Trial Application (CTA) approval for the first-in-human Phase I/IIa clinical trial of ITOP1, the company's lead 'off-the-shelf' cancer vaccine. ITOP1 is a precision cancer vaccine ...

The aim is to give approved researchers easy access to data without them having to “navigate different systems or make multiple applications for information for the same project,” the government’s ...